Skip to main content
GLUE
NASDAQ Life Sciences

Officer Edmund Dunn Files Intent to Sell $345K in Shares Acquired via Option Exercise

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
7
Price
$20.71
Mkt Cap
$1.75B
52W Low
$4.12
52W High
$25.77
Market data snapshot near publication time

Summary

An officer of Monte Rosa Therapeutics, Edmund Dunn, has filed a Form 144 indicating an intent to sell approximately $345,000 worth of shares, which were acquired through a same-day option exercise.


Key Events

  • Officer Files Intent to Sell Shares

    Edmund Dunn, an officer of Monte Rosa Therapeutics, Inc., has filed a Form 144 indicating an intent to sell 16,665 shares of common stock.

  • Proposed Sale Value

    The proposed sale has an approximate market value of $344,985.50.

  • Shares Acquired via Option Exercise

    The shares intended for sale were acquired through a stock option exercise on the same day as the proposed sale date, suggesting a liquidity or tax-related disposition.

  • Ongoing Insider Distribution

    This filing contributes to a pattern of insider share distribution, with Edmund Dunn having already sold $1,096,624.22 in shares over the past three months.


Analysis

Officer Edmund Dunn has filed an intent to sell shares valued at approximately $345,000. While the shares were acquired through a same-day option exercise, often a liquidity event, this transaction adds to a pattern of ongoing insider share distribution. Dunn has already sold over $1 million in shares in the past three months, indicating a consistent reduction in direct equity exposure by a key executive.

At the time of this filing, GLUE was trading at $20.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $4.12 to $25.77. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GLUE - Latest Insights

GLUE
Jun 23, 2026, 4:02 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $20.71
Real-time Price: $20.81 info
Change: +$0.100 (+0.48%) info
Market Cap: $1.75B info
GLUE
Jun 01, 2026, 4:29 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $19.67
Real-time Price: $20.81 info
Change: +$1.14 (+6%) info
Market Cap: $1.75B info
GLUE
May 07, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.33
Real-time Price: $20.81 info
Change: +$0.480 (+2%) info
Market Cap: $1.75B info
GLUE
May 07, 2026, 7:28 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $20.35
Real-time Price: $20.81 info
Change: +$0.460 (+2%) info
Market Cap: $1.75B info
GLUE
May 07, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.35
Real-time Price: $20.81 info
Change: +$0.460 (+2%) info
Market Cap: $1.75B info
GLUE
May 01, 2026, 4:53 PM EDT
Filing Type: 144
Importance Score:
10
Price at Filing: $18.80
Real-time Price: $20.81 info
Change: +$2.01 (+11%) info
Market Cap: $1.75B info
GLUE
Mar 17, 2026, 7:14 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $15.87
Real-time Price: $20.81 info
Change: +$4.94 (+31%) info
Market Cap: $1.75B info
GLUE
Mar 17, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.87
Real-time Price: $20.81 info
Change: +$4.94 (+31%) info
Market Cap: $1.75B info
GLUE
Mar 17, 2026, 7:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $15.87
Real-time Price: $20.81 info
Change: +$4.94 (+31%) info
Market Cap: $1.75B info
GLUE
Mar 16, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.40
Real-time Price: $20.81 info
Change: +$4.41 (+27%) info
Market Cap: $1.75B info